Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxurion NVLTS:0G99 9 Receivables Turnover is 0.44 as of Dec. 2025. GuruFocus rates LTS:0G99 with a GF Score™ of 9/100 and a GF Value™ of €1.05. The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Oxurion NV ranks worse than 95.12% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Oxurion NV's Revenue for the
six
months ended in Dec. 2025 was €0.56 Mil. Oxurion NV's average Accounts Receivable for the
six
months ended in Dec. 2025 was €1.25 Mil.
Hence, Oxurion NV's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.44.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Oxurion NV Receivables Turnover Related Terms
Oxurion NV Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Oxurion NV's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0G99 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Oxurion NV's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxurion NV Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxurion NV's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Oxurion NV's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxurion NV (LTS:0G99) has a Receivables Turnover of 0.44 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oxurion NV and its competitors. According to the industry distribution chart, Oxurion NV ranks #800 out of 841 companies in the Biotechnology industry, placing it in the top 95.1%.
Is Oxurion NV's Receivables Turnover too high?
Oxurion NV's current Receivables Turnover is 0.44. The Biotechnology industry median Receivables Turnover is 5.28. Oxurion NV's value of 0.44 is 91.7% below this industry median. Based on the distribution chart, Oxurion NV ranks #800 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxurion NV has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Oxurion NV's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxurion NV ranks #800 out of 841 companies for Receivables Turnover. This places Oxurion NV in the lower half of its industry. The industry median Receivables Turnover is 5.28. Oxurion NV's value of 0.44 is 91.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxurion NV's current Receivables Turnover of 0.44 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Oxurion NV and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxurion NV's current Receivables Turnover is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxurion NV stock overvalued right now?
Oxurion NV (LTS:0G99) has a current Receivables Turnover of 0.44. The stock's GF Value™ is €1.05, compared to a current price of €0.27 — trading 74% below its estimated fair value. The current Receivables Turnover is 0.44 and 91.7% below the Biotechnology industry median of 5.28. Oxurion NV's overall GF Score™ is 9/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Oxurion NV (LTS:0G99), the current Receivables Turnover is 0.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxurion NV (LTS:0G99) Overvalued in 2026?
Based on GuruFocus' analysis, Oxurion NV stock appears to be undervalued.
The current stock price of €0.27 is trading 74% below its estimated GF Value™ of €1.05.
Key valuation signals for LTS:0G99:
Receivables Turnover: 0.44
GF Value™: €1.05 vs. price of €0.27 (74% below fair value)
Industry Position: 91.7% below the Biotechnology median (#800 of 841)
No single metric tells the full story. See the LTS:0G99 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.
9GF Score
Get the complete analysis for LTS:0G99
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G99 has been successfully added to your 
